Zynex Inc. (ZYXI) Raised to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Zynex Inc. (OTCMKTS:ZYXI) from a hold rating to a buy rating in a research report released on Thursday morning. Zacks Investment Research currently has $3.25 target price on the stock.

According to Zacks, “Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. “

A number of other brokerages also recently weighed in on ZYXI. ValuEngine downgraded Zynex from a buy rating to a hold rating in a report on Tuesday, October 31st. Taglich Brothers reaffirmed a speculative buy rating on shares of Zynex in a report on Monday, August 21st.

Zynex (OTCMKTS ZYXI) opened at $3.00 on Thursday. Zynex has a 52 week low of $0.25 and a 52 week high of $3.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.19 and a current ratio of 1.27. The company has a market capitalization of $98.50, a price-to-earnings ratio of 23.08 and a beta of 0.71.

Zynex (OTCMKTS:ZYXI) last posted its quarterly earnings data on Monday, November 13th. The company reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.01. Zynex had a negative return on equity of 248.78% and a net margin of 24.10%. The firm had revenue of $6.82 million for the quarter, compared to analyst estimates of $5.52 million. equities analysts forecast that Zynex will post 0.17 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Zynex Inc. (ZYXI) Raised to “Buy” at Zacks Investment Research” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/27/zynex-inc-zyxi-raised-to-buy-at-zacks-investment-research.html.

Zynex Company Profile

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply